The Benefits and Risks of HRT: What Current Research Shows

Hormone replacement therapy has been studied for decades, yet few areas of medicine have generated as much confusion among patients.

Some people have heard that hormone replacement therapy, or HRT, substantially increases the risk of cancer, heart attack, and stroke. Others encounter claims suggesting that nearly everyone should use hormones for energy, longevity, weight management, or disease prevention.

Neither extreme accurately reflects the evidence.

Current research shows that hormone therapy can provide important benefits when it is prescribed for an appropriate patient, for an appropriate medical indication, at an appropriate dose. It also carries real risks that vary considerably depending on the hormones being used, the patient's age and health history, the route of administration, treatment duration, and other individual factors.

For women, the balance of benefits and risks surrounding menopausal hormone therapy has become considerably more nuanced as researchers have reexamined earlier studies and accumulated additional long-term data. For men with confirmed testosterone deficiency, newer research has also clarified several questions surrounding cardiovascular safety.

This article examines what we currently know about the potential benefits, limitations, and risks of HRT—and why hormone treatment should be individualized rather than approached as a one-size-fits-all therapy.

If you are new to the subject, you may first want to read our overview of hormone replacement therapy or explore our complete Hormone Replacement Therapy Resource Center.

What Does Hormone Replacement Therapy Mean?

Hormone replacement therapy is an umbrella term describing treatment that supplements hormones when the body's natural production has declined or when a clinically significant hormone deficiency is present.

The hormones involved depend on the patient.

For women approaching or experiencing menopause, treatment most commonly involves estrogen. Women who still have a uterus generally require appropriate endometrial protection with a progestogen when using systemic estrogen.

For men with established hypogonadism, treatment may involve testosterone replacement therapy.

The indications, benefits, risks, and monitoring requirements are different for these therapies. It is therefore misleading to describe all forms of HRT as equally beneficial or equally risky.

You can learn more about available formulations in our complete guide to hormone replacement therapy.

Why HRT Became So Controversial

Much of the modern concern surrounding menopausal hormone therapy can be traced to the Women's Health Initiative, or WHI, a large randomized study whose hormone-therapy findings were first reported in 2002.

The trial provided critically important information, but its results were sometimes interpreted much more broadly than the study population and treatment regimens justified.

Many participants were considerably older than women who typically begin treatment for menopausal symptoms, and the original combination arm studied oral conjugated equine estrogen together with medroxyprogesterone acetate.

Subsequent research has demonstrated that the effects of hormone therapy can differ depending on when treatment begins, which hormones are used, whether estrogen is given orally or through the skin, whether a woman has a uterus, and the patient's underlying medical risks.

The Menopause Society now states that for most healthy symptomatic women younger than 60 years or within approximately 10 years of menopause onset, the benefit-risk ratio of menopausal hormone therapy is generally favorable.

The WHI remains enormously important. The lesson from the research that followed, however, is that its findings should not be interpreted to mean that every form of hormone therapy carries the same risks for every woman.

What Changed With HRT Safety Warnings in 2026?

One of the most important recent developments occurred in February 2026.

The U.S. Food and Drug Administration approved labeling changes for menopausal hormone therapy products removing references to cardiovascular disease, breast cancer, and probable dementia from the boxed warning for affected products. The FDA has also pursued broader labeling changes intended to provide a more individualized description of hormone therapy's benefits and risks.

That does not mean these risks have disappeared.

The FDA specifically stated that cardiovascular and breast-cancer information continues to appear elsewhere in product warnings and precautions when appropriate. The endometrial-cancer boxed warning associated with systemic unopposed estrogen in women with a uterus also remains an important consideration.

The change is therefore best understood as a move away from treating menopausal hormone therapy as though one risk profile applies equally to every patient, formulation, and stage of life.

Benefit #1: HRT Is Highly Effective for Hot Flashes and Night Sweats

The clearest indication for systemic menopausal hormone therapy remains relief of bothersome vasomotor symptoms.

Hot flashes and night sweats can significantly interfere with sleep, concentration, work, mood, and overall quality of life.

Estrogen-containing menopausal hormone therapy remains the most effective available treatment for these symptoms. The Menopause Society considers hormone therapy a first-line treatment for appropriate patients with bothersome vasomotor symptoms.

Improvement in sleep may occur as night sweats and temperature instability improve, although hormone therapy should not automatically be considered a treatment for every type of insomnia.

Benefit #2: HRT Can Treat Vaginal and Urinary Symptoms of Menopause

Declining estrogen can affect tissues of the vagina, vulva, urethra, and bladder.

The resulting condition is often called genitourinary syndrome of menopause, or GSM.

Symptoms may include vaginal dryness, burning, discomfort, painful intercourse, urinary irritation, and recurrent urinary symptoms.

Low-dose vaginal estrogen can be particularly useful when symptoms are primarily localized to the vaginal and urinary tissues.

Because systemic absorption with appropriately dosed local vaginal estrogen is very low, the treatment has a different risk profile from systemic hormone therapy. The Menopause Society and other medical organizations recognize local vaginal hormone therapy as an important treatment option for GSM.

Women with a history of hormone-sensitive cancer require individualized decision-making with their treating clinicians, but the existence of such a history does not mean every local therapy should automatically be viewed the same way as systemic estrogen.

Benefit #3: Menopausal Hormone Therapy Helps Preserve Bone

Estrogen plays an important role in maintaining bone density.

After menopause, declining estrogen contributes to accelerated bone loss and increasing osteoporosis risk.

Randomized clinical trials have demonstrated that menopausal hormone therapy reduces bone loss and decreases fracture risk while treatment is being used.

This does not mean every woman with osteopenia or osteoporosis should begin HRT. Other osteoporosis medications may be more appropriate depending on age, fracture history, bone density, and other risk factors.

For a symptomatic woman near menopause who also has concerns about bone loss, however, bone protection may be an additional benefit considered when evaluating the overall treatment decision.

What Does Research Show About HRT and Heart Disease?

This is one of the areas where timing matters most.

Hormone therapy should not simply be prescribed as a medication to prevent cardiovascular disease. However, evidence suggests that cardiovascular outcomes differ substantially depending on when treatment begins.

Women who initiate menopausal hormone therapy relatively close to menopause generally have a more favorable overall benefit-risk profile than women who first begin systemic therapy many years later.

The Endocrine Society's review of the evidence similarly describes more favorable coronary heart disease and mortality findings among younger women and those closer to menopause than among women starting therapy substantially later.

Route also matters.

Oral estrogen passes through the liver before reaching the systemic circulation and has greater effects on certain clotting proteins. Transdermal estrogen delivered by a patch, gel, or spray avoids this first-pass hepatic effect.

For patients with certain cardiovascular or thromboembolic risk factors, transdermal estradiol may therefore be preferred over oral estrogen.

Hormone therapy should nevertheless not be viewed as a substitute for controlling blood pressure, cholesterol, smoking, diabetes, physical inactivity, or other established cardiovascular risk factors.

Does HRT Increase the Risk of Blood Clots?

Systemic estrogen can increase the risk of venous thromboembolism, including deep-vein thrombosis and pulmonary embolism.

The magnitude of that risk depends partly on how estrogen is administered.

Oral estrogen generally produces a greater thrombotic effect than transdermal estrogen. This is one reason treatment route may be an important part of individualized prescribing.

A personal history of blood clots, known thrombophilia, smoking, obesity, prolonged immobility, and other factors may influence the decision.

This is also why asking simply, “Is estrogen safe?” is less useful than asking, “Which estrogen, by which route, for which patient?”

HRT and Breast Cancer: What Does the Evidence Actually Show?

Breast cancer is understandably one of the concerns patients most frequently raise.

The evidence is more complicated than the statement that “HRT causes breast cancer.”

In the Women's Health Initiative randomized trial, treatment with conjugated equine estrogen plus medroxyprogesterone acetate was associated with an increased incidence of breast cancer.

The estrogen-alone arm, which involved women who had undergone hysterectomy, did not show the same pattern. Long-term follow-up of the randomized estrogen-alone group actually demonstrated lower breast-cancer incidence and breast-cancer mortality compared with placebo.

These findings do not establish that estrogen should be prescribed to prevent breast cancer.

They do demonstrate that estrogen alone and estrogen combined with a progestogen should not automatically be assigned the same breast-cancer risk profile.

Risk can also be influenced by treatment duration, the specific progestogen used, baseline breast-cancer risk, alcohol consumption, obesity, family history, breast density, previous biopsies, and other factors.

For women at increased baseline risk, these considerations deserve a more detailed discussion before systemic therapy is prescribed.

Why Progesterone Matters When a Woman Has a Uterus

Systemic estrogen stimulates the endometrial lining.

When estrogen is used without adequate opposing progestogen in a woman who still has a uterus, endometrial hyperplasia can develop and the risk of endometrial cancer increases.

Appropriate progesterone or another progestogen is therefore generally included to protect the uterine lining.

This is one risk that has not disappeared with the FDA's newer labeling approach. The FDA continues to maintain an endometrial-cancer boxed warning for systemic estrogen-alone therapy in women with a uterus.

Unexpected or persistent postmenopausal bleeding should always be medically evaluated rather than assumed to be a harmless side effect of HRT.

What About HRT and Dementia?

Hormone therapy should not be prescribed solely for the purpose of preventing dementia.

Earlier WHI Memory Study findings raised concerns about dementia among women who began certain systemic hormone regimens at age 65 or older.

Those findings should not automatically be extrapolated to a woman beginning treatment around age 50 for menopausal symptoms, but current evidence is also insufficient to recommend systemic HRT as a dementia-prevention strategy.

Age at initiation appears to matter, and research into the relationship between estrogen, brain aging, and cognition continues.

The FDA's 2026 removal of probable dementia from the boxed warning reflects the need for more individualized interpretation, not proof that hormone therapy prevents cognitive decline.

Are “Bioidentical” Hormones Safer?

The word bioidentical can be confusing because it is used in several different ways.

FDA-approved estradiol and micronized progesterone are chemically identical to hormones produced naturally by the human body and are often described as bioidentical.

Compounded hormone preparations are different.

Although customized compounded medications can occasionally have an appropriate role, compounded products generally do not undergo the same FDA review for consistency, potency, efficacy, and safety as approved medications.

The Endocrine Society has cautioned that there is insufficient evidence to conclude that compounded bioidentical hormone therapy is inherently safer or more effective than FDA-approved hormone therapy.

“Natural” or “bioidentical” therefore should not be interpreted as meaning risk-free.

What Does the Research Show About Testosterone Therapy for Men?

Testosterone replacement therapy presents a different set of questions.

Testosterone treatment is generally intended for men with symptoms or clinical features of testosterone deficiency together with consistently low testosterone concentrations confirmed through appropriate testing.

It should not be prescribed solely because a single laboratory value falls near the lower end of a reference range.

The Endocrine Society recommends establishing an appropriate diagnosis and evaluating potential causes of low testosterone before treatment is initiated.

Men considering treatment can read our article about hormone testing and interpretation and our guide to determining whether HRT may be appropriate.

Potential Benefits of Testosterone Replacement Therapy

For appropriately diagnosed hypogonadal men, testosterone replacement may improve sexual desire and certain aspects of sexual function.

Research also suggests potential improvement in anemia, lean body mass, and bone density in selected men.

The American Urological Association notes evidence for improvement in erectile function, libido, anemia, bone mineral density, lean body mass, and depressive symptoms in some testosterone-deficient men.

Patients should be cautious, however, about advertisements suggesting that testosterone reliably restores youthful energy, eliminates fatigue, dramatically improves cognition, or functions as a general anti-aging medication.

Fatigue, reduced motivation, difficulty concentrating, weight gain, and decreased exercise tolerance have many possible causes. Low testosterone should be diagnosed rather than assumed.

Testosterone and Cardiovascular Risk: What Changed?

The cardiovascular safety of testosterone therapy has been debated for many years.

A major advance came from the TRAVERSE trial, a large randomized cardiovascular-safety study involving men with confirmed hypogonadism and established cardiovascular disease or significant cardiovascular risk.

Testosterone therapy was not associated with a higher rate of major adverse cardiovascular events than placebo during the trial.

Following review of these findings, the FDA announced class-wide labeling changes in February 2025 removing the previous boxed warning regarding increased risk of major cardiovascular events from testosterone products.

The story does not end there.

Studies required by the FDA also demonstrated that testosterone products can increase blood pressure. Updated labeling therefore emphasizes blood-pressure monitoring and cardiovascular risk assessment.

TRAVERSE also identified signals involving several other events, including atrial fibrillation, acute kidney injury, and pulmonary embolism, that deserve continued investigation rather than being ignored.

The appropriate conclusion is therefore not that testosterone has “no cardiovascular risk.” It is that evidence has become more reassuring regarding major cardiovascular events in appropriately selected men while continuing to support thoughtful patient selection and monitoring.

Important Risks of Testosterone Therapy

One of the most common clinically important effects of testosterone treatment is an increase in red blood-cell production.

For some men, hematocrit can rise excessively, creating erythrocytosis and potentially increasing blood viscosity. Hemoglobin and hematocrit therefore require monitoring.

Testosterone can also reduce sperm production—sometimes dramatically—because external testosterone suppresses the hormonal signaling required for normal testicular testosterone and sperm production.

Men who are currently trying to conceive or who may want fertility in the future should discuss this before treatment begins.

Additional potential effects include acne, oily skin, fluid retention, changes in prostate-related symptoms, breast tenderness or enlargement, and worsening of certain sleep-related breathing disorders in susceptible individuals.

The Endocrine Society recommends appropriate evaluation and ongoing monitoring when testosterone therapy is used.

Does Testosterone Cause Prostate Cancer?

Current evidence has not demonstrated that appropriately prescribed testosterone replacement inevitably causes prostate cancer.

That does not mean prostate risk can be ignored.

Men should receive age- and risk-appropriate prostate evaluation before and during therapy when indicated, particularly when PSA values or symptoms raise concern.

A known or suspected prostate malignancy requires a different level of evaluation and specialist involvement.

The objective is not to avoid testosterone simply because the prostate exists, nor to assume testosterone has no prostate-related implications.

It is to monitor appropriately.

HRT Risks Are Not Determined by One Laboratory Number

One of the most important principles in hormone medicine is that laboratory values cannot be interpreted in isolation.

A hormone level must be considered alongside symptoms, age, timing of collection, medications, menstrual status when applicable, medical history, physical findings, and the clinical question being investigated.

For example, diagnosing testosterone deficiency generally requires appropriate symptoms plus consistently low morning testosterone measurements rather than a single isolated value.

Likewise, menopausal hormone therapy is usually prescribed primarily according to symptoms, reproductive stage, medical history, and risk profile rather than attempting to make every estrogen or progesterone level match a predetermined “optimal” number.

If you are considering treatment, our guide to blood, saliva, and urine hormone testing explains why different testing methods are useful in different circumstances.

Who May Need Extra Caution Before Starting HRT?

The safety assessment should be individualized.

For menopausal hormone therapy, clinicians may need to give particular attention to a history of breast or endometrial cancer, unexplained vaginal bleeding, previous blood clots, stroke, coronary disease, significant liver disease, migraine patterns, gallbladder disease, smoking, and other cardiovascular risk factors.

For testosterone therapy, considerations include fertility goals, elevated hematocrit, severe untreated obstructive sleep apnea, prostate findings, cardiovascular history, blood pressure, and certain recent cardiovascular events.

These circumstances do not all carry identical levels of risk, and some represent relative rather than absolute contraindications.

The purpose of the evaluation is to determine whether treatment is appropriate and, when it is, which formulation and monitoring strategy make the most sense.

Route, Dose, and Formulation Matter

A major reason modern HRT discussions have become more nuanced is that “hormone therapy” does not describe one medication.

Estrogen may be delivered orally, transdermally, or locally through vaginal preparations.

Testosterone may be delivered through injections, gels, patches, oral formulations, or other methods.

Progesterone and synthetic progestins also differ pharmacologically.

Each route has advantages and disadvantages involving absorption, convenience, side effects, dose flexibility, laboratory monitoring, and potential risk.

This is why the safest treatment is not necessarily the product with the most appealing marketing terminology. It is the treatment whose evidence, pharmacology, dose, and route best match the individual patient's needs.

How Long Can Someone Stay on HRT?

There is no universal rule stating that every patient must discontinue hormone therapy after a specific number of years or at a particular birthday.

For menopausal hormone therapy, current guidance emphasizes periodic reassessment rather than an automatic stopping point.

The Menopause Society has stated that hormone therapy does not necessarily need to be routinely discontinued solely because a woman reaches age 60 or 65. Continued therapy may be reasonable for selected patients after ongoing assessment of symptoms, health status, and changing risks.

Similarly, testosterone therapy may continue when a clear indication remains, the patient is benefiting, laboratory findings remain appropriate, and significant adverse effects have not developed.

Treatment should be periodically reassessed rather than placed on autopilot.

What Current Research Ultimately Tells Us About HRT

The modern evidence does not support a simple conclusion that hormone replacement therapy is either universally dangerous or universally beneficial.

For many healthy women with significant menopausal symptoms—particularly those who begin treatment before age 60 or within approximately 10 years of menopause—the benefits of appropriately selected hormone therapy can outweigh the risks.

For men with genuine hypogonadism, testosterone therapy can provide clinically meaningful benefits, but treatment requires an accurate diagnosis and appropriate monitoring rather than being prescribed as a general anti-aging therapy.

The most important lesson from decades of HRT research is therefore personalization.

Age matters.

Timing matters.

Medical history matters.

The specific hormone matters.

The route of administration matters.

The dose matters.

And the reason the patient is taking the medication matters.

Hormone therapy should be a shared medical decision based on the individual's symptoms, health risks, treatment goals, and the best available evidence.

Considering Hormone Replacement Therapy in Arizona?

If symptoms such as hot flashes, night sweats, vaginal discomfort, decreased libido, persistent fatigue, reduced sexual function, or other concerns have led you to wonder whether hormones may be involved, the first step is usually a comprehensive medical evaluation rather than automatically beginning treatment.

At Ask Dr. Hu, hormone care for men and women includes review of symptoms, medical history, medications, relevant laboratory results, treatment goals, contraindications, and ongoing monitoring when therapy is prescribed.

You can also explore our Hormone Replacement Therapy Resource Center for additional physician-written guides about HRT options, testing, safety, and treatment.

Hormone therapy is not appropriate for everyone, and treatment recommendations should always be individualized.

Medical Review and Evidence Standards

This article was developed using current evidence and guidance from major medical and regulatory sources, including The Menopause Society, the U.S. Food and Drug Administration, the Endocrine Society, the American Urological Association, and major randomized clinical trials published in journals including The New England Journal of Medicine and JAMA.

Medical evidence surrounding hormone therapy continues to evolve. Recommendations may change as additional long-term studies become available. Individual treatment decisions should therefore be based on current medical evidence as well as the patient's personal health history and risk factors.

This information is intended for general educational purposes and does not replace individualized medical advice, diagnosis, or treatment.

About the Author

YiQiu Hu, NMD

Dr. YiQiu Hu is an Arizona-licensed naturopathic physician and the founder of Ask Dr. Hu. His clinical work focuses on concierge medicine, preventive healthcare, health optimization, laboratory evaluation, chronic disease management, medical weight management, hormone care, and individualized treatment planning.

Dr. Hu created Ask Dr. Hu to provide patients with a more accessible and relationship-centered healthcare experience built around longer conversations, direct physician communication, continuity of care, and practical medical guidance.

He earned his Doctor of Naturopathic Medicine degree from Sonoran University of Health Sciences and a Bachelor of Science in Biomedical Sciences from Northern Arizona University. In addition to patient care, Dr. Hu has experience in medical leadership and multidisciplinary healthcare practice management.

Learn more about Dr. YiQiu Hu and the physicians at Ask Dr. Hu.